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Abstract: Current recommendations for counteracting obesity advocate the consumption 
of a healthy diet and participation in regular physical activity, but many individuals have 
difficulty complying with these recommendations. Studies in rodents and humans have 
indicated that long-chain omega-3 polyunsaturated fatty acids (LC n-3 PUFA) potentially 
elicit  a  number  of  effects  which  might  be  useful  for  reducing  obesity,  including 
suppression  of  appetite,  improvements  in  circulation  which  might  facilitate  nutrient 
delivery to skeletal muscle and changes in gene expression which shift metabolism toward 
increased  accretion  of  lean  tissue,  enhanced  fat  oxidation  and  energy  expenditure  and 
reduced fat deposition. While LC n-3 PUFA supplementation has been shown to reduce 
obesity in rodents, evidence in humans is limited. Epidemiological associations between 
LC n-3 PUFA intakes and obesity are inconclusive but small cross-sectional studies have 
demonstrated inverse relationships between markers of LC n-3 PUFA status and markers 
of  obesity.  Human  intervention  trials  indicate  potential  benefits  of  LC  n-3  PUFA 
supplementation, especially when combined with energy-restricted diets or exercise, but 
more well-controlled and long-term trials are needed to confirm these effects and identify 
mechanisms of action. 
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1. Introduction 
Obesity is increasing in epidemic proportions throughout the developed and developing world [1,2] 
bringing with it increased morbidity and mortality [3,4]. If we are to avoid prohibitive increases in 
health costs, and adverse health consequences for an increasing proportion of society, feasible and 
affordable strategies to combat the rising prevalence of obesity must be found. 
Current  recommendations  from  most  public  health  bodies  for  reducing  body  fat  are  based  on 
increasing physical activity [5] and eating a healthy balanced diet [6]. However, many people have 
difficulty complying with these lifestyle changes, particularly over the longer term. Indeed, a recent 
meta-analysis showed that almost half of any initial weight loss achieved through diet or exercise is 
regained after one year [7]. Hence, despite widespread recommendations from public health bodies to 
improve diet and physical activity habits the prevalence of obesity continues to rise. Accordingly, 
more acceptable and sustainable strategies for reducing body fat must be found. 
Considerable efforts have been directed to investigating the benefits of the long-chain omega-3 
polyunsaturated  fatty  acids  (LC  n-3  PUFA),  notably  eicosapentaenoic  acid  (EPA)  and 
docosahexaenoic acid (DHA), for improving cardiovascular health and reducing cardiovascular disease 
(CVD) risk. However, despite the current obesity epidemic and a growing body of evidence indicating 
that the regular consumption of these fatty acids can influence fat metabolism, little attention has been 
paid to the potential for EPA and DHA to reduce obesity. 
This review extends the work described in a previous review by these authors [8], providing a more 
detailed examination of the included studies and introducing the potential effects of LC n-3 PUFA on 
lean tissue accretion as a mechanism for obesity reduction. 
2. LC n-3 PUFA and Body Fat Reduction in Animals 
2.1. Protection against Body Fat Gain 
A growing number of studies have shown that incorporating LC n-3 PUFA into high-fat obesogenic 
diets fed to rodents reduces body fat accumulation [9-13], although one study in diabetic rats reported 
that supplementing a high-fat diet with LC n-3 PUFA exacerbated, rather than reduced, weight gain [14].  
Cunnane et al. [11] fed 6-week old male ln/ln and ob/ob C57BL/6J mice synthetic diets that were 
supplemented with 10% (w/w) evening primrose oil (predominantly omega-6 (n-6) PUFA) or 10% cod 
liver oil (predominantly LC n-3 PUFA) for 16 weeks. Overall, the ob/ob mice gained significantly 
more weight than the ln/ln mice irrespective of the diet consumed. The ob/ob mice that consumed the 
cod  liver  oil  finished  the  study  with  a  significantly  lower  body  weight  than  the  ob/ob  mice  that 
consumed the evening primrose oil, but this was due in part to a slight difference in starting weights as 
the  tendency  for  less  weight  gain  in  the  animals  fed  the  cod  liver  oil  did  not  reach  statistical 
significance compared with evening primrose oil. The difference in body weight between treatment 
groups was not related to differences in energy intake, but was instead ascribed to differences in 
incorporation of LC n-3 and n-6 PUFA into liver, brown adipose tissue and white adipose tissue. The 
ob/ob mice fed the cod liver oil demonstrated greater incorporation of LC n-3 PUFA and reduced 
incorporation of n-6 PUFA into these tissues which has the potential to influence gene expression that 
would alter their metabolic activity leading to reductions in body fat accumulation [15]. Nutrients 2010, 2  
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Hainault et al. [12] subsequently fed six week old male Wistar rats one of three high-fat diets (50% 
of energy) or a low fat control diet (10% corn oil, 20% casein, 70% starch) ad libitum for 16–20 days. 
The  high  fat  diets  consisted  of  48%  lard,  2%  corn  oil  (high-lard  diet),  35%  lard,  15%  corn  oil 
(lard-corn oil diet) or 33% lard, 2% corn oil and 15% fish oil (lard-fish oil diet), together with 20% 
casein and 30% starch. Food intake and body weights were similar for all diets, but rats consuming the 
lard-fish oil diet had 20% and 30% less subcutaneous (inguinal) and visceral (retroperitoneal and 
epididymal) adipose tissue respectively by the end of the study period, suggesting that the fish oil had 
provided a protective benefit against the accumulation of body fat.  
Belzung et al. [10] demonstrated that this protective effect of fish oil exhibited a dose-response 
relationship. They fed 7-week old male Wistar rats a control diet (standard chow) or one of three 
high-fat diets (20% fat w/w) containing high, medium and low LC n-3 PUFA content (40.6%, 18.6% 
and 0.7% of fatty acids, respectively) for four weeks. The three high fat diets resulted in greater body 
fat accumulation compared with the control diet, with no differences in increases in body weight, 
subcutaneous fat or mesenteric fat. However, the accumulation of epididymal fat was less in the high 
LC n-3 PUFA group and there was a dose dependent attenuation of the increase in retroperitoneal fat 
mass.  These  differences  in  epididymal  and  retroperitoneal  fat  were  due  to  reduced  adipocyte 
hypertrophy  rather  than  to  any  reduction  in  adipocyte  number.  The  authors  proposed  that  the 
reductions  in  fat  were  mediated  by  a  lowering  of  circulating  triglycerides  given  that  plasma 
triglyceride concentrations were lower with the medium and high LC n-3 PUFA treatments, and the 
plasma triglyceride concentrations correlated positively with retroperitoneal and epididymal adipocyte 
size. The reduction in adipocyte hypertrophy was consistent with the findings of an earlier study by 
Parrish  et  al.  [16].  Parrish  and  co-workers  fed  male  Wistar  Rats  high-fat  diets  containing 
20% triglycerides from fish oil or 20% triglycerides from lard for three weeks and found no difference 
in body weight, but significantly less perirenal and epididymal fat in the fish oil fed group. This effect 
was the result of a reduction in adipocyte size with no difference in adipocyte number. Thus, it appears 
that the protective benefits of LC n-3 PUFA against the accumulation of body fat may be achieved 
through a lesser accumulation of fat in existing adipocytes, with these effects being primarily evident 
in visceral fat depots and exhibiting a dose-response relationship. 
The preferential reduction in the accumulation of visceral fat has been confirmed in two subsequent 
studies [9,13]  and  may  be  mediated  primarily  by  DHA [13].  Baillie  et  al.  [9]  fed  two  groups  of  
3–4 week old male Fisher 344 rats a high fat diet containing 40% of energy as either fish oil or corn oil 
for six weeks. Epididymal fat pads from rats fed the fish oil diet weighed 25% less than those of the 
rats fed corn oil by the end of the six week study period. Ruzickova et al. [13] subsequently fed  
3–4 month old male C57BL/6 mice a low-fat control diet (3.4% fat (w/w)), one of two high-fat control 
diets (20.0% and 35.2% fat (w/w)), or one of seven experimental diets which consisted of the high-fat 
control diets admixed with 15% or 45% (w/w) EPA or DHA for five weeks. By the end of the study 
period it was found that EPA and DHA attenuated the accumulation of epididymal fat, but had a 
limited effect on the accumulation of subcutaneous fat. Importantly, it was further determined that this 
effect  was  promoted  by  a  low  ratio  of  EPA/DHA,  suggesting  that  DHA,  rather  than  EPA,  was 
primarily responsible for promoting the anti-obesity effect of an increased LC n-3 PUFA intake. 
Therefore,  there  are  a  number  of  studies  in  rodents  which  indicate  that  the  dietary  intake  of 
LC n-3 PUFA  can  attenuate  increases  in  diet-induced  obesity,  particularly  increases  in  visceral Nutrients 2010, 2  
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(epididymal fat). However, a recent study [14] which compared feeding different high-fat diets for 
six weeks on the development of obesity in male C57BL/KsJ-lepr
db/lepr
db mice with diabetes found 
that  feeding  a  high-fat  diet  (30%  of  energy)  containing  LC  n-3  PUFA  exacerbated  weight  gain 
compared with the same diet containing safflower oil (rich in n-6 fatty acids). This exacerbation of 
weight gain only occurred in mice with diabetes; in non-diabetic mice the safflower diet resulted in 
increased weight gain compared with a low-fat control diet but the LC n-3 PUFA diet did not result in 
any greater weight gain. As body fat was not measured, it is unclear whether the differences in weight 
gain between diets were due to differences in body fat deposition. Nevertheless, the increased weight 
gain in the mice with diabetes fed the LC n-3 PUFA diet suggests that these fatty acids may exert quite 
different metabolic effects in diabetes, at least in mice. 
2.2. LC n-3 PUFA for Reducing Existing Obesity 
While a number of studies in rodents have shown that the incorporation of LC n-3 PUFA into an 
obesogenic diet can attenuate the accumulation of body fat, at least in non-diabetic animals, there have 
been limited studies which have examined whether incorporating LC n-3 PUFA into a diet can reduce 
established  adiposity.  In  the  only  study  to  specifically  examine  this  question,  Huang  et  al.  [17] 
demonstrated that the intake of LC n-3 PUFA could reduce body fat in mice that had been made obese 
by prior feeding of a high-fat diet. In this study, male C57B1/l mice were fed a high fat (59% of 
energy)  or  low-fat  (10%  of  energy)  control  diet  for  13  weeks.  The  mice  were  then  classified  as 
diet-induced obese or diet-resistant according to whether they fell within the upper or lower tertiles of 
body weight gain. The diet-induced obese mice were then subjected to a six week dietary intervention 
which consisted of feeding either the original high fat diet, a high fat diet with a high LC n-3 PUFA 
content (59% of energy from fish oil), or the low-fat control diet. The LC n-3 PUFA and low-fat diets 
reduced  body  weight  to  the  same  level  as  the  diet  resistant  mice  and  the  controls  that  had  been 
maintained on the low-fat diet, indicating that both LC n-3 PUFA and a low-fat diet were effective for 
weight loss. The loss of body weight after the mice were switched to the LC n-3 PUFA diet could not 
be attributed to a reduction in food intake. However, the mice that were switched to the LC n-3 PUFA 
diet exhibited the lowest food efficiencies (i.e., lowest weight gain per unit energy intake) indicating 
that the LC n-3 PUFA reduced metabolic efficiency. 
Therefore, it appears that, in rodent models, the dietary intake of LC n-3 PUFA may be effective for 
retarding  body  weight  and  body  fat  gain  during  the  consumption  of  an  obesogenic  diet,  and  for 
reducing body weight in animals that are already obese. However, there is evidence, albeit somewhat 
limited, that the dietary intake of LC n-3 PUFA may exert different metabolic effects in diabetic 
animals, resulting in an exacerbation of weight gain when a high-fat obesogenic diet is consumed. 
3. LC n-3 PUFA and Body Fat Reduction in Humans 
While there is evidence from a considerable number of animal studies that LC n-3 PUFA can 
reduce  body  fat,  their  impact  on  body  composition  in  humans  is  less  certain  due  to  a  lack  of 
appropriately  designed  studies  of  adequate  size  and  duration.  Furthermore,  despite  dietary  energy 
restriction  and/or  exercise  being  the  cornerstones  of  treatment  for  obesity,  few  studies  have 
investigated the efficacy of LC n-3 PUFA for reducing body fat when combined with these treatments. Nutrients 2010, 2  
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3.1. Observational Studies—Relationships between LC n-3 PUFA Intake and Body Weight 
A number of large long-term prospective cohort studies have examined the effects of LC n-3 PUFA 
supplementation on cardiovascular health but none have specifically examined effects on body weight 
or body fat. Nevertheless, the Health Professional Follow-Up Study, a prospective cohort study with 
12  years  of  follow-up  which  examined  the  effects  of  LC  n-3  PUFA  intake  on  risk  of  stroke  in 
43,671 men [18], reported that, at baseline, men with high fish consumption (consuming fish ≥5 times 
per week) were less likely to be overweight than those with low fish consumption (consuming fish less 
than once per month), and the percentage of overweight volunteers was inversely related to the LC n-3 
PUFA intake. Conversely, in the Nurses’ Health Study [19], which was a prospective cohort study in 
79,839 women with a 14 year follow-up which examined the relationship between the intake of fish 
and LC n-3 PUFA and the risk of stroke, higher intakes of fish and LC n-3 PUFA were associated with 
a  higher  prevalence  of  obesity,  with  the  proportion  of  participants  with  a  body  mass  index 
(BMI) ≥ 29 kg/m
2 increasing progressively as fish intake increased from less than once per month to 
≥5 times  per  week.  While  the  higher  prevalence  of  obesity  associated  with  fish  intake  could  be 
accounted for by a higher energy intake, this was not the case for LC n-3 PUFA intake. 
Thus, the limited evidence available from large prospective cohort studies which have assessed the 
potential relationships between LC n-3 PUFA intake and body weight is conflicting. It is not clear 
whether  the  different  findings  of  the  two  studies  that  have  investigated  this  issue  are  due  to 
confounding  or to  gender differences in  the effect of LC  n-3 PUFA  on body  fat. This raises the 
possibility that the effect of LC n-3 PUFA on reducing body weight and/or body fat in humans may be 
limited to males. 
A  limitation  of  the  large  epidemiological  studies  is  that  dietary  intakes  are  assessed  using 
semi-quantitative food frequency questionnaires which might not be particularly sensitive in terms of 
their ability to accurately quantify intakes of particular fatty acids. A different approach is to use tissue 
content  of  LC  n-3  PUFA  as  a  biomarker  of  intake.  Garaulet  et  al.  [20]  examined  the  fatty  acid 
composition  of  adipose  tissue  samples  of  84  obese  patients  (BMI  27–35  kg/m
2)  and  found  that 
abdominal  obesity  as  assessed  by  waist-hip  ratio  and  visceral  abdominal  fat  area  (by  computed 
tomography) were inversely related to the LC n-3 PUFA content (in particular the DHA content) of 
perivisceral and omental adipose tissue samples. In a subsequent study, the same group showed that 
the LC n-3 PUFA content of the subcutaneous adipose tissue (but not other adipose tissue depots) was 
inversely related to adipocyte size [21]. Taken together, these data indicate that a higher LC n-3 PUFA 
status  is  associated  with  reduced  abdominal  obesity  as  a  result  of  a  reduction  in  adipocyte  size. 
Similarly, in a more recent study, Micaleff et al. [22] measured plasma LC n-3 PUFA concentrations 
as a biomarker of dietary LC n-3 PUFA intake in 124 healthy adults (BMI 20–40 kg/m
2) and reported 
that the plasma LC n-3 PUFA levels (% of total plasma fatty acids) were inversely related to BMI, 
waist circumference and hip circumference, again suggesting that a higher plasma LC n-3 PUFA status 
might protect against obesity.  
3.2. Randomized Controlled Trials 
While cross-sectional studies are useful for identifying associations between LC n-3 PUFA intake 
and obesity, they cannot demonstrate a cause and effect relationship since people who consume a high Nutrients 2010, 2  
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intake of LC n-3 PUFA might also undertake other diet and/or lifestyle practices which could account 
for lower body fat. In order to directly assess the effects of LC n-3 PUFA intake on body composition 
in humans, randomized controlled trials are required. Such trials are few in number; hence there is 
little information regarding effects of LC n-3 PUFA on body composition when consumed either alone 
or in conjunction with dietary energy restriction and/or regular exercise. 
3.2.1. Effect of LC n-3 PUFA Intake Alone on Body Composition 
Couet et al. [23] conducted a single-blind intervention trial in which six healthy adults (5 male, 
1 female) consumed a control diet (52% carbohydrate, 16% protein, 32% fat; as % of energy intake) 
for three weeks then, after a 10–12 week washout, consumed the same diet but with 6 g/day of visible 
fat replaced with fish oil (providing 1.1 g/day EPA and 0.7 g/day DHA). At the beginning and end of 
each dietary period resting metabolic rate and fat oxidation were measured by indirect calorimetry and 
body composition was assessed by dual-energy x-ray absorptiometry (DXA). Dietary intakes (7 day 
recall) and physical activity (by activity recall) were completed two weeks prior to each experimental 
period to monitor any changes in diet or physical activity. Resting fat oxidation was increased (22%) 
and body fat was reduced (−0.88 kg) on the fish oil diet; these differences were not accounted for by 
any differences in dietary intake or physical activity. However, one major limitation of this study was 
that, rather than balancing the order in which the dietary treatments were undertaken, all volunteers 
consumed the control diet followed by the fish oil diet and this may have introduced an order effect, 
potentially confounding the outcome. 
Subsequently, Kabir et al. [24] studied the effects of supplementation with LC n-3 PUFA on body 
composition in 27 overweight and obese postmenopausal women with type 2 diabetes. Subjects were 
randomized  in  a  double-blind  parallel  study  design  to  consume  3  g/day  of  EPA-rich  fish  oil 
(1.08 g EPA, 0.72 g DHA) or 3 g/day of paraffin oil for two months. Body composition was assessed 
by DXA and subcutaneous and visceral fat cross-sectional areas were determined by a single-slice 
computerized  tomography  (CT)  scan  at  the  L4–L5  disc  space  level.  A  biopsy  of  subcutaneous 
periumbilical adipose tissue was also collected. By the end of the study period, neither treatment group 
had  reduced  their  body  weight  and  there  were  no  changes  in  subcutaneous  or  visceral  fat 
cross-sectional areas assessed by CT. However, the LC n-3 PUFA group reduced their body fat mass 
significantly (~1.6 kg); this reduction was primarily due to a loss of trunk fat. The authors attributed 
the discrepancy in findings between the CT scans and DXA as being due to limited sensitivity of a 
single-slice CT scan for detecting changes in abdominal fat combined with the fact that DXA assessed 
fat lost from the whole of the trunk and not just the abdomen at the level of the CT slice. Participants 
randomized to the fish oil treatment also experienced a reduction in adipocyte diameter, whereas this 
did not change in the control group. The finding of a reduction in adiposity in these postmenopausal 
women with type 2 diabetes is in contrast to the aforementioned study by Todoric et al. [14] in diabetic 
mice wherein dietary LC n-3 PUFA supplementation exacerbated increases in body fat during high fat 
feeding. The reason for the discrepancy in findings between these two studies is not clear, but it is 
possible that effects of LC n-3 PUFA on body composition are regulated differently in mice that are 
genetically predisposed to diabetes, and humans who develop type 2 diabetes as a result of lifestyle 
habits. The findings from the study by Kabir et al. [24] also refute the possible gender influences on 
body fat reduction observed in large cohort studies [18,19]. Nutrients 2010, 2  
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3.2.2. Effect of LC n-3 PUFA Intake Combined with Dietary Energy Restriction on Body Composition 
Dietary energy restriction is widely accepted as a cornerstone in the management of obesity and a 
number of studies have examined whether supplementing the diet with LC n-3 PUFA can enhance the 
weight loss that can be achieved through dietary restriction. 
Fontani et al. [25] investigated the effects of LC n-3 PUFA supplementation against a background 
of body fat reduction using two different controlled diets. Thirty three non-competitive athletes were 
randomized  to  consume  either  a  low-carbohydrate  Zone  diet  (40%  carbohydrate,  30%  protein, 
30% fat) or a diet recommended by the Italian National Research Institute for Nutrition and Foods 
(55% carbohydrate, 15% protein, 30% fat) for 70 days. Half of the volunteers on each dietary pattern 
were further randomized to consume 4 g/day of fish oil (1.6 g EPA, 0.8 g DHA) or 4 g/day of olive oil 
in a cross-over design (i.e., consume fish oil for 35 days and then cross over to olive oil, or vice versa). 
Body fat was assessed by skinfolds at baseline, and at the end of each 35 day period. The two diets 
both reduced body fat by approximately 7%, but there was no additional effect of LC n-3 PUFA 
supplementation. However this study had serious limitations: The oil supplementation periods may 
have been too short to see effects on body composition and there may have been a carry-over effect of 
LC  n-3  PUFA  accumulation  in  various  tissues  confounding  the  outcome  in  those  volunteers  who 
received  LC  n-3  PUFA  initially.  Incorporation  of  LC  n-3  PUFA  into  tissues  (e.g.,  erythrocyte 
membranes) has been shown to increase by as much as 150% when provided at a similar dose and 
timeframe (35 days) to that employed by Fontani et al. [26]. Retention of LC n-3 PUFA in these 
tissues is prolonged, and levels can remain elevated for up to 18 weeks [27].  
More  recently,  Krebs  et  al.  [28]  examined  the  effect  of  adding  LC  n-3  PUFA  to  a  low-fat 
high-carbohydrate  weight  loss  diet  on  body  weight  and  body  composition  in  overweight  women. 
Ninety three overweight women completed the study in which they were randomized to the weight loss 
diet (3.3–3.8 MJ/day; 15% protein, 35% fat, 50% carbohydrate) combined with LC n-3 PUFA (5 g fish 
oil containing 1.3 g EPA, 2.9 g DHA per day) or placebo (5 g oil containing 2.8 g linoleic acid, 1.4 g 
oleic acid per day), or to a control condition (no weight loss diet) for five weeks to facilitate acute 
weight loss. This was followed by a staged reintroduction of energy intake to meet weight maintenance 
requirements (~10,400 kJ/day) by the end of 12 weeks. Body composition was assessed at baseline and 
after 12 and 24 weeks by DXA. Body weight did not change in the control group, but fell ~12% in 
both dietary treatment groups, with no difference in the magnitude of weight loss between LC n-3 
PUFA and placebo. Similarly, body fat did not change in the control group but was reduced by a 
similar amount in both diet groups. Therefore, the findings of this study did not provide any support 
for  greater  weight  loss  or  differential  changes  in  body  composition  when  LC  n-3  PUFA 
supplementation is combined with an energy restricted diet in overweight women.  
In the most recent study to examine the effects of LC n-3 PUFA intake on body composition when 
consumed  in  conjunction  with  an  energy  restricted  diet,  Thorsdottir  et  al.  [29]  randomized 
278 overweight men and women to one of four isocaloric energy-restricted diets (2500 kJ/day caloric 
restriction, 50% carbohydrate, 20% protein, 30% fat) for eight weeks. The diets contained no seafood 
(control), lean fish (150 g cod three times per week, 0.3 g LC n-3 PUFA/day), fatty fish (150 g salmon 
three times per week, 3.0 g LC n-3 PUFA/day), or fish oil (6 ×  1 g capsules yielding 1.5 g LC n-3 
PUFA/day). The average weight loss was 6.5 kg for men (~7% body weight) and 4.2 kg for women Nutrients 2010, 2  
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(~5% body weight). Weight loss and reductions in waist circumference were significantly greater in 
the groups receiving fish or fish oil compared with controls (~1 kg greater weight loss over the first 
4 weeks) but these differences were limited to male volunteers. The finding of additional weight loss 
not only with the fish oil diet but also with the lean and fatty fish diets was interpreted by the authors 
as suggesting that weight loss might have been facilitated by fish protein which is rich in the amino 
acid taurine, since taurine has been shown to decrease body weight in mice [30]. However, the fatty 
fish and fish oil diets (which provided a higher LC n-3 PUFA intake) tended to provide greater weight 
loss than the lean fish diet even though there was no significant difference in the weight loss achieved 
between the three diets. This suggests that LC n-3 PUFA may provide some small additional benefit 
for  weight  loss,  even  when  the  background  intake  of  LC  n-3  PUFA  is  high  as  the  erythrocyte 
phospholipid content of LC n-3 PUFA was >9% of total phospholipids in all groups, reflecting a high 
basal LC n-3 PUFA intake. 
The  finding  of  a  significantly  greater  weight  loss  in  male  volunteers  only  in  the  study  by 
Thorsdottir et al. [29] suggests that the lack of any additional weight loss in the study by Krebs et al. [28] 
when LC n-3 PUFA were added to an energy restricted diet may have been because only females were 
evaluated.  However,  too  few  studies  have  been  conducted  to  date  to  confirm  any  gender  related 
difference in the efficacy of LC n-3 PUFA to promote additional improvements in body composition 
when combined with an energy restricted diet. 
3.2.3. Effect of LC n-3 PUFA Intake Combined with Regular Exercise on Body Composition 
In addition to energy restriction, increasing physical activity is widely advocated to improve body 
composition in obesity. As a result, a number of studies have examined whether combining LC n-3 
PUFA supplementation with a program of regular exercise provides any additional improvements in 
body composition beyond what might be achieved through exercise alone. 
Warner et al. [31] randomized thirty four dyslipidemic adults with ~30% body fat to a control group 
(usual lifestyle) or one of three treatment groups. For 12 weeks the treatment groups consumed either 
50 mL of corn oil per day, 50 mL of fish oil per day (17% EPA, 12% DHA), or consumed 50 mL of 
fish oil and undertook a progressive aerobic exercise program which consisted of walking or jogging 
three days  per  week  for  45–50  min  at  70–85%  of  maximal  heart  rate.  Body  composition  was 
determined by hydrostatic weighing at baseline and after the 12 week intervention, and dietary intake 
was  assessed  by  48  hr  dietary  recall.  The  volunteers  who  undertook  the  exercise  program  and 
consumed fish oil exhibited a 3% reduction in body fat, while body fat was unchanged in the other 
groups.  However,  the  lack  of  an  exercise  control  (i.e.,  no  group  undertook  an  exercise  only 
intervention)  made  it  impossible  to  determine  whether  this  reduction  in  body  fat  was  due  to  the 
exercise alone or to some interaction between the fish oil and exercise. 
Brilla and Landerholm subsequently investigated the effects of 10 weeks of fish oil supplementation 
and exercise on body composition in healthy, previously sedentary young males [32], but included an 
exercise control group in the study design. Thirty-two healthy young male volunteers were randomized 
to four groups: control, fish oil, exercise, or fish oil and exercise. The fish oil groups consumed 4 g/day 
of LC n-3 PUFA. The exercise groups performed aerobic exercise for one hour three times per week. 
Percent  body  fat  (hydrostatic  weighing)  and  dietary  intake  (3  day  diet  records)  were  assessed  at Nutrients 2010, 2  
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baseline and after 10 weeks. Body fat did not decrease significantly in any treatment group. Unlike 
previous studies in which LC n-3 PUFA had been shown to reduce body fat in overweight and obese 
volunteers, the young male volunteers in this study were lean (15–20% body fat) which may have 
limited the capacity for the LC n-3 PUFA to provide any reduction body fat. Indeed, the use of a lean 
population may also have accounted for the lack of any reduction in body fat with exercise. 
More  recently,  Hill  et  al.  [33]  studied  the  effects  of  exercise  and  fish  oil  supplementation  in 
overweight and obese adults. Participants were randomized (double-blind) to consume 6 g/day of fish 
oil containing ~1.9 g LC n-3 PUFA (26% DHA, 6% EPA) or 6 g/day of sunflower oil for 12 weeks. 
Half of the volunteers in each oil treatment group were further randomized to maintain their usual 
physical activity or undertake a program of regular exercise which involved walking three times per 
week for 45 min at 75% of their age-predicted maximum heart rate. Assessment of 3-day weighed food 
records from 65 subjects who completed the intervention indicated that there were no differences in 
energy intake between treatment groups. Body weight was reduced by the exercise but there was no 
effect  of  LC  n-3  PUFA.  However,  both  exercise  and  LC  n-3  PUFA  supplementation  exerted 
independent  (but  additive)  effects  on  body  fat  reduction;  volunteers  who  undertook  exercise  and 
LC n-3 PUFA supplementation lost ~1.6 kg of body fat over 12 weeks (see Figure 1). Without the 
exercise  program,  a  modest  reduction  of  body  fat  was  achieved  by  regular  supplementation  with 
~1.9 g/day of LC n-3 PUFA compared with sunflower oil (predominantly n-6 PUFA). Further studies 
should be undertaken to evaluate the effects of higher doses of LC n-3 PUFA over longer time frames 
on body fat reduction in overweight and obese populations. 
Figure  1.  Dual-energy  X-ray  absorptiometry  assessed  changes  in  body  fat  mass  after 
supplementation with 6 g/day of docosahexaenoic acid-rich fish oil, 6 g/day sunflower oil, 
fish oil and exercise or sunflower oil and exercise for 12 weeks in overweight and obese 
adults. * Significant oil ×  time and exercise ×  time interactions were detected (P < 0.05). 
Adapted from Hill et al. [33] with permission from the American Society for Nutrition. 
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3.2.4. Effect of LC n-3 PUFA Intake Combined with Dietary Energy Restriction and Regular Exercise 
on Body Composition 
While some studies have examined whether combining LC n-3 PUFA with diet or exercise provides 
any additional benefit for improving body composition, only one study has examined the combination 
of  LC  n-3  PUFA  with  both  dietary  energy  restriction  and  a  program  of  regular  exercise. 
Kunešová  et al. [34] reported a 1.5 kg greater weight loss over a 3-week period in severely obese 
women who undertook a regular exercise program combined with consuming a very low-calorie diet 
that was supplemented with 2.8 g/day of LC n-3 PUFA (predominantly EPA), compared with those 
undertaking the exercise program while consuming the very low-calorie diet but receiving a placebo. 
Twenty seven severely obese women underwent a one week outpatient weight stabilization period, 
followed  by  a  three  week  inpatient  weight  reduction  period.  During  the  weight  reduction  period 
volunteers undertook 60 min/day of light to moderate physical activity and were randomly assigned to 
consume either a very low calorie diet (2200 kJ/day) supplemented with 2.8 g/day of LC n-3 PUFA 
(2:1 ratio of EPA to DHA) or the very low calorie diet supplemented with saline solution. Weight loss 
was greater in the LC n-3 PUFA supplemented group but did not quite reach statistical significance 
(7.6 ±  1.8 vs. 6.1 ±  2.2 kg, P < 0.10), whereas there were significantly greater reductions in body mass 
index (2.8 ±  0.6 vs. 2.2 ±  0.7 kg/m
2, P < 0.05) and hip circumference (4.8 ±  1.8 vs. 2.5 ±  2.5 cm, 
P < 0.05) in this treatment group compared with controls. The reduction in body mass index was 
inversely related to the incorporation of DHA into plasma phospholipids (r = −0.60, P < 0.008). While 
body fat changes were not reported, the authors did find a greater increase in serum beta-hydroxybutyrate 
in the LC n-3 PUFA supplemented group compared with control, and interpreted this as providing 
evidence of greater fat oxidation in this treatment group. These findings indicate that the addition of 
LC n-3 PUFA to a relatively short (3 week) weight loss program comprising severe caloric restriction 
and exercise may increase fat oxidation leading to greater improvement in body composition. 
The finding of this study contrasts with the study by Krebs et al. [28] which reported no additional 
reduction in body weight when LC n-3 PUFA were combined with caloric restriction. The reason for 
the discrepant findings is not immediately obvious; both studies combined caloric restriction with  
3–4 g/day of LC n-3 PUFA to achieve weight loss in overweight and/or obese women. A possible 
explanation may lie in the magnitude of weight loss achieved, with the study by Krebs et al. [28] 
achieving approximately double the weight loss reported in the study by Kunešová et al. (12% of body 
weight vs. 6% of body weight) [34]. It is therefore possible that the much larger weight loss achieved 
in the study by Krebs et al. [28] may have masked any additional weight loss that might have been 
achieved as a result of LC n-3 PUFA supplementation. 
3.3. Summary of Effects of LC n-3 PUFA Intake on Body Composition in Humans 
In summary, evidence indicates that increasing the intake of LC n-3 PUFA by 0.3–3.0 g/day is 
effective  for  reducing  body  weight  and  improving  body  composition  in  humans.  However,  these 
findings come from short-term studies (3–12 weeks in duration) and have for the most part shown that 
LC n-3 PUFA promote modest reductions in body weight and improvements in body composition 
when taken either alone, or in conjunction with an energy restricted diet. There is an important need to Nutrients 2010, 2  
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examine the longer-term effects of LC n-3 PUFA supplementation on body fat in overweight and 
obese adults and thereby determine if LC n-3 PUFA supplementation may be an effective long-term 
strategy for body fat reduction. 
4. Mechanisms of Body Fat Reduction with LC n-3 PUFA 
Increasing the dietary intake of LC n-3 PUFA by 0.3–3.0 g/day may assist with body weight and 
body  fat  reduction  by  multiple  mechanisms.  One  mechanism  is  through  an  enhancement  of 
post-prandial satiety which might lead to reduced food intake. Another mechanism, and one for which 
there is the most evidence, is through alterations in the expression of genes involved in the regulation 
of fat oxidation in adipose, liver, cardiac, intestinal and skeletal muscle tissue, and in the regulation of 
adipogenesis in adipose tissue. These effects on gene expression favoring enhanced fat oxidation and 
reduced fat deposition.  
4.1. Appetite Effects 
Most studies in animals and humans which have shown effects of LC n-3 PUFA on body weight 
and/or body composition indicate that these effects are independent of energy intake [11,12,17,33]. 
However, a recent sub-analysis (n = 233) [35] of a larger weight loss study (n = 278) [29] which 
showed that weight loss achieved through caloric restriction was enhanced when fish or fish oil was 
included in the diet, indicated that the intake of LC n-3 PUFA was associated with greater satiety 
immediately after and 120 min after a test meal. Appetite was assessed during the final two weeks of 
the eight week dietary intervention in which volunteers had been randomly assigned to one of four 
isocaloric energy restricted diets (2,100–3,500 kJ/day restriction) consisting of a control diet which 
contained no seafood, a diet containing lean fish (0.3 g LC n-3 PUFA/day), a diet containing fatty fish 
(3.0 g LC n-3 PUFA/day), or a diet including six fish oil capsules per day (1.5 g LC n-3 PUFA/day). 
Weight loss and decrease in waist circumference was significantly greater in the groups receiving fish 
or fish oil compared with controls (~1 kg greater weight loss over the first four weeks), but in male 
volunteers  only.  For  the  sub-study  a  validated  visual  analogue  scale  was  used  to  assess  hunger 
sensations (fullness, hunger) directly after and two hours after a test meal consisting of 22% protein, 
30% fat and 48% carbohydrate. The test meal supplied 35% of the prescribed daily energy intake  
(1.8–2.9 MJ) and food included in the test meals was representative of the different group specific 
diets with regard to inclusion of lean or fatty fish and LC n-3 PUFA intake. The visual analogue scale 
assessment revealed higher sensations of fullness in the volunteers who consumed the higher LC n-3 
PUFA content meals (fatty fish and fish oil) compared with those who consumed the lower LC n-3 
PUFA content meals (control and lean fish groups) immediately after and two hours after consuming 
the meal. Feelings of hunger were also lower in the higher LC n-3 PUFA groups two hours after the 
test  meal.  The  authors  concluded  that  LC  n-3  PUFA  intake  modulates  postprandial  satiety  in 
overweight and obese volunteers during weight loss and postulated that this might improve compliance 
with the nutritional treatment of overweight and obesity. Thus, it is possible that increased feelings of 
satiety following a meal containing a high LC n-3 PUFA content might reduce subsequent food intake, 
leading to improvements in weight loss and body composition. However, additional research is required.  Nutrients 2010, 2  
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4.2. Effects on Expression of Genes Regulating Metabolic Pathways 
Mitochondrial carnitine palmitoyl transferase I (CPT-I) exchanges coenzyme  A for carnitine to 
facilitate the transfer of acyl groups into the mitochondria for β-oxidation in liver, cardiac muscle and 
skeletal muscle cells, and is the main control point for β-oxidation. The mitochondrial expression of 
CPT-I  is  regulated  upstream  by  peroxisome  proliferator-activated  receptors  (PPARs)  [36]  and  by 
5'-AMP-activated protein kinase (AMPK), with the latter having recently been shown to be activated 
by EPA in both adipose tissue [37] and skeletal muscle [38]. This activation of AMPK by EPA might 
account  for  the  earlier  observation  by  Power  and  Newsholme  of  an  increase  in  CPT-1  with  an 
increased dietary intake of LC n-3 PUFA [39]. Power and Newsholme [39] fed male weanling Lewis 
rats ad libitum for up to 10 weeks on either a low fat diet (25 g corn oil/kg) or one of five high fat 
diets, comprising 200 g/kg of hydrogenated coconut oil, olive oil, safflower oil, evening primrose oil 
or EPA rich menhaden (fish) oil. Groups of 12–18 rats were fed each diet and groups of 4–6 animals 
were removed after 2, 4 and 10 weeks for analysis of cardiac CPT-I and after 4 and 10 weeks for 
analysis of skeletal muscle CPT-I. Rats fed the EPA-rich menhaden oil had significantly greater CPT-I 
specific activity in heart and skeletal muscle and significantly greater CPT-1 tissue capacity in skeletal 
muscle compared with rats fed the low fat diet. While some of the safflower oil and evening primrose 
oil diets also increased CPT-I specific activity in the heart, only menhaden oil increased mitochondrial 
CPT-I activity in skeletal muscle. In rats fed menhaden oil, cardiac and skeletal muscle CPT-I had 
lower sensitivity to inhibition by malonyl CoA compared with rats fed the low fat diet. This lower 
sensitivity of CPT-I would also be likely to contribute to increased fat oxidation by maintaining a 
higher CPT-I activity in the face of other dietary effects on CPT-I regulation by malonyl CoA [40]. 
The increased expression of CPT-I in heart and skeletal muscle as a result of increased LC n-3 PUFA 
intake is likely to contribute to regulation of the balance between fat and carbohydrate oxidation by 
promoting an increased transport of fatty acids into the mitochondria and their subsequent oxidation. 
Apart from increases in heart and skeletal muscle CPT-I, supplementing the diet of rats with LC n-3 
PUFA has also been shown to increase the expression of uncoupling protein 3 (UCP-3) mRNA in 
skeletal muscle, and the expression of peroxisomal acyl-CoA oxidase in skeletal muscle, liver and 
heart [9]. Baillie et al. [9] fed two groups of 3-4 week old male Fisher 344 rats (n = 5 per group) a diet 
containing 40% of energy from corn oil or fish oil for six weeks, after which time the epididymal  
(i.e., visceral) fat pads from the rats fed the fish oil diet weighed 25% less than those of the rats fed the 
corn oil. This decrease in fat deposition was associated with a significant increase in the abundance of 
skeletal muscle UCP-3 mRNA and an increase in peroxisomal acyl-CoA oxidase gene expression in 
liver, skeletal muscle and heart. An increase in peroxisomal fatty acid oxidation is important in terms 
of regulating energy balance because it is a much less efficient pathway for energy production than 
mitochondrial  β-oxidation,  yielding  30–40%  more  heat  and  30%  less  ATP  than  mitochondrial 
oxidation [41]. An increase in peroxisomal acyl-CoA oxidase gene expression suggests that LC n-3 
PUFA increase the oxidative capacity of this pathway. Additionally, uncoupling proteins reduce the 
efficiency  of  mitochondrial  oxidative  phosphorylation  by  inducing  mitochondrial  proton  leakage, 
resulting in a reduced ATP yield from oxidative phosphorylation and an increase in heat production. 
Thus,  the  combination  of  an  increase  in  the  expression  of  uncoupling  proteins  and  peroxisomal 
acyl-CoA oxidase would be expected to result in a reduction in overall metabolic efficiency, thereby Nutrients 2010, 2  
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potentially contributing to an increased loss of energy in the form of heat and less storage of energy in 
the form of fat. 
In addition to these studies which have demonstrated alterations in gene expression in skeletal 
muscle, liver and cardiac muscle, Mori et al. [42] examined the effects of supplementing the diet with 
LC n-3 PUFA on body fat accumulation and the potential role of changes in intestinal gene expression 
in  mediating  a  reduction  in  body  fat  accumulation.  Mori  and  coworkers  divided  obesity-prone 
C57BL/6J mice into five treatment groups and fed them a low fat diet (5% triglyceride by weight), or 
one  of  four  high  fat  diets  (30%  by  weight)  for  five  months.  The  high  fat  diets  consisted  of 
30% triglyceride, or 2%, 4% or 8% fish oil with the balance made up of triglyceride. The animals 
supplemented with 8% fish oil plus 22% triglyceride exhibited an attenuation (P < 0.05) of body 
weight  increase  (13.7 g increase) compared with the  30% triglyceride diet (20.8 g increase).  The 
increase in body weight in this treatment group did not differ from that of the mice fed the low-fat 
(5%)  diet  (14.6 g).  The  differences  in  body  weight  gain  between  the  8%  fish  oil  group  and  the 
30% triglyceride  group  could  not be  accounted  for  by  differences  in  energy intake.  However,  the 
attenuation of weight gain in the 8% fish oil group was associated with increased intestinal expression 
of genes coding for CPT 1a, cytochrome P450 4A10 and malic enzyme and 1.2-, 1.6- and 1.7-fold 
increases in enzymes of β-oxidation, ω-oxidation and malic enzyme respectively compared to those 
receiving the 30% triglyceride diet. The authors concluded that the anti-obesity effect of fish oil was 
associated with an up-regulation of intestinal lipid oxidation.  
Therefore,  part  of  the  mechanism  by  which  LC  n-3  PUFA  reduce  body  fat  may  be  through 
promotion of fat oxidation and, in particular, the less efficient peroxisomal oxidation of fat combined 
with less efficient mitochondrial substrate oxidation due to upregulation of uncoupling proteins in 
liver,  cardiac  muscle  and  particularly  skeletal  muscle  which  is  a  major  site  for  whole  body  lipid 
metabolism [43], as well as through an increase in intestinal lipid oxidation. Taken together, these 
effects would be expected to lead to increased but less efficient fat oxidation (and potentially less 
efficient mitochondrial oxidation of other substrates), contributing to a reduced availability of substrate 
for uptake and storage of fat by adipose cells. 
While these effects on intestinal tissue, skeletal muscle, liver and heart may promote fat oxidation 
and reduce metabolic efficiency in these tissues, contributing to a reduction in substrate availability for 
storage  by  adipose  cells,  there is  also  evidence  that  feeding  fish  oil  influences  fat  metabolism  in 
adipose tissue itself. Indeed, there is evidence that LC n-3 PUFA results in changes in gene expression 
in adipose tissue which favor the oxidation of fat and reduce the capacity to synthesize fat in visceral 
fat depots. 
Flachs et al. [44] fed 4-month old male C57BL/6J mice for four weeks on two diets containing 
20% fat (w/w), with the fat in these diets consisting of either flaxseed oil (rich in α-linolenic acid 
(ALA, a short chain n-3 PUFA) or flaxseed oil admixed with an LC n-3 PUFA concentrate (6% EPA, 
51% DHA). Two further groups of mice were fed for five weeks on two diets containing 35% fat 
(w/w), one very low in LC n-3 PUFA and the other admixed with LC n-3 PUFA concentrate which 
replaced 15% of the dietary lipids. Mice on the LC n-3 PUFA supplemented diets had significantly 
lower  body  weights  and  epididymal  (i.e.,  visceral)  fat  weights  by  the  end  of  the  study  periods 
compared with mice on the non-LC n-3 PUFA supplemented diets but there were no differences in 
dorsolumbar (i.e., subcutaneous) fat weight. The greater reduction in epididymal fat with the LC n-3 Nutrients 2010, 2  
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PUFA  supplemented  diets  was  associated  with  increased  β-oxidation  and  decreased  fatty  acid 
synthesis  in  epididymal  fat  and  the  upregulation  of  a  number  of  genes  coding  for  mitochondrial 
proteins. In particular there was an up-regulation of peroxisome proliferator-activated receptor gamma 
coactivator 1α (PGC-1α), CPT-I and nuclear respiratory factor-1 (NRF-1) in epididymal fat but not 
subcutaneous  fat.  Given  that  PGC-1α  is  an  upstream  regulator  of  mitochondrial  biogenesis  and 
oxidative metabolism, while CPT-I regulates fatty acid entry to the mitochondria and NRF-1 regulates 
mithochondrial biogenesis [45], these changes in gene expression would be expected to increase the 
capacity of epididymal fat to oxidize fatty acids. This was observed as an increase in β-oxidation in 
this tissue, as assessed by the release of radioactivity into tissue culture medium from fragments of 
adipose tissue prelabelled with [9,10(n)-
3H]oleic acid. The diets admixed with LC n-3 PUFA also 
resulted in a reduction in expression of stearoyl-CoA desaturase mRNA (a key enzyme in the lipogenic 
pathway) in epididymal fat, and this was associated with a reduction in fatty acid synthesis in this 
tissue  as  assessed  by 
3H2O  incorporation  into  saponifiable  fatty  acids.  Thus,  taken  together,  the 
findings of this study by Flachs et al. [44] indicate that LC n-3 PUFA increase the expression of genes 
in epididymal (i.e., visceral) fat which favor fatty acid oxidation and reduce fatty acid synthesis. 
Overall, an increased oxidation of fat in heart, liver, skeletal muscle and visceral fat would lead to a 
reduction in availability of substrate for deposition in adipose tissue, while a reduced capacity to store 
fat as a result of reduced expression of lipogenic genes in this tissue would contribute to an overall 
reduction in body fat. While the aforementioned alterations in gene expression would favor a reduction 
in body fat, many of these changes are not necessarily specific for individual LC n-3 PUFA. A recent 
preliminary  study  using  microarray  analysis  of  genes  regulated  by  dietary  fatty  acids  has  shown 
considerable overlap in the influence of different PUFA on PPARs and other nuclear receptors [46]. 
Therefore, the net influence on fat metabolism will be determined by a complex integration of the 
effects of individual PUFA on gene expression. 
4.3. Effects on Tissue Anabolism and Maintenance of Lean Tissue Mass 
There is some evidence from a limited number of animal studies which suggests that LC n-3 PUFA 
may alter the activity of anti-catabolic and/or anabolic pathways in skeletal muscle to promote the 
maintenance  of  lean  tissue  mass.  Any  such  promotion  of  lean  tissue  mass  would  be  expected  to 
increase metabolic rate, and might therefore contribute indirectly to reductions in body fat. EPA has 
been shown to suppress activation of the ubiquitin-proteasome pathway [47], which is the key pathway 
responsible  for  muscle  proteolysis  during  energy  restriction  [48],  by  impairing  activation  of  the 
transcription factor NF-, an important regulator of this pathway [47,49]. An increased intake of LC 
n-3 PUFA has also been shown to increase whole body protein synthesis via the activation of key 
regulatory kinases involved in muscle protein synthesis, specifically mTOR and S6K in steers [50]. 
These potential anti-catabolic and anabolic effects of LC n-3 PUFA may attenuate muscle loss and 
promote  the  maintenance  of  muscle  mass  (and  metabolic  rate)  during  periods  of  dietary  energy 
restriction,  or  potentially  increase  muscle  mass  during  energy  balance.  Additional  studies  of  the 
potential for LC n-3 PUFA to maintain lean tissue mass during energy restriction appear warranted, 
particularly in humans. Nutrients 2010, 2  
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4.4. Effects on Muscle Blood Flow 
Arterial vasodilator function [51,52] and skeletal muscle blood flow [53] are impaired in obesity 
and are associated with reduced nutrient disposal [54]. We recently demonstrated that supplementation 
with 1.9 g/day of LC n-3 PUFA improved vasodilator function [33] while Walser et al. [55] showed 
that increased LC n-3 PUFA (5 g/day) increased skeletal muscle blood flow during exercise. Thus, 
some of the observed reductions in body fat with LC n-3 PUFA may be in part due to improved 
vasodilator  function  increasing  blood  flow  and  nutrient  delivery  to  skeletal  muscle  resulting  in 
improved nutrient utilization for energy production and less conversion to fat storage. No studies have 
directly addressed this hypothesis, but given the inter-relationships between obesity, skeletal muscle 
blood flow and nutrient disposal, additional studies seem warranted. 
5. Conclusions 
There is a considerable body of evidence from rodent studies indicating that supplementing the diet 
with LC n-3 PUFA can attenuate weight gain and reduce body fat, in particular epididymal (visceral) 
fat. Similarly, in human studies there is a growing body of evidence indicating that increasing the 
intake of LC n-3 PUFA by 0.3–3.0 g/day can reduce body weight and body fat in overweight and 
obese individuals. 
The  mechanism  by  which  increasing  the  intake  of  LC  n-3  PUFA  by  such  an  amount  
(i.e., 0.3–3.0 g/day) may improve body composition is most likely altered gene expression favoring 
increased fat oxidation in adipose, liver, cardiac, intestinal and skeletal muscle tissue and reduced fat 
deposition in adipose tissue. There is some preliminary evidence that an increase in LC n-3 PUFA 
intake within this dose range might also attenuate postprandial sensations of hunger, although the 
majority of studies, including those in rodents, which have reported improved body composition, have 
not reported any reduction in food (i.e., energy) intake. Data from a number of studies also suggest that 
LC n-3 PUFA might promote increases in lean tissue mass, thus potentially increasing metabolic rate 
and indirectly assisting with body fat reduction. It is also possible that the increases in vasodilator 
function and muscle blood flow during exercise that result from supplementation with 1.9–5.0 g/day of 
LC n-3 PUFA might promote nutrient disposal by skeletal muscle, thus reducing the availability of 
nutrients for lipogenesis and storage in adipose tissue. 
While there is growing evidence that LC n-3 PUFA can improve body composition in humans, 
there is still much controversy because the majority of studies have been of relatively short duration 
and the magnitude of the improvements have been modest. Accordingly, there is an urgent need for 
longer-term  studies  to  determine  the  relative  effects  of  EPA  and  DHA  supplementation  on  body 
composition and the feasibility of using LC n-3 PUFA supplementation as a strategy to improve body 
composition in overweight and obese populations.  Nutrients 2010, 2  
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